VENUSREMNSEVenus Remedies Limited· PharmaceuticalsMediumNeutral
Announced Tue, 26 May · 22:27 IST

Venus Remedies Limited has informed the Exchange regarding Appointment of Mr Saransh ChaudhARY as Whole Time Directors of the company w.e.f. May 26, 2026.

Promoter Family Board EntryManagement Changes View source PDF

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.3%1-day move
₹1160.00
prior close
₹1219.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.0+0.0+10.3+15.9+21.7+27.7+34.1+41.9+48.5+66.3+35.6
Up moveDown movePending
AI summary

Venus Remedies Limited has appointed Mr. Saransh Chaudhary as Whole Time Director effective May 26, 2026. He is related to Mr. Pawan Chaudhary (Managing Director) and holds 15,68,000 shares in the company. The Board meeting on May 26, 2026 also approved audited financial results showing strong performance - Revenue from Operations grew to Rs. 768.73 Crores (up 19.3% from Rs. 644.47 Crores) and Net Profit surged to Rs. 99.31 Crores (up 89% from Rs. 52.55 Crores). Basic EPS stands at Rs. 74.29. The Board recommended a 100% final dividend of Rs. 10 per share, subject to shareholder approval at the 37th AGM scheduled for August 20, 2026 (record date August 7, 2026). Multiple board appointments and reappointments were also approved including Dr. Savita Guta's reappointment as Independent Director and Mr. Peeyush Jain as Additional Director.

Likely market impact

The appointment of a promoter family member as Whole Time Director indicates succession planning within the Chaudhary family. Strong financial results with near-doubling of net profit and a 100% dividend payout are positive signals for shareholders, suggesting healthy cash generation and shareholder-friendly policies.